PINK1
PINK1 is one of the classic genes linked to early-onset Parkinson’s disease. Clinically, PINK1-related disease often resembles typical Parkinson’s, with bradykinesia, rigidity, and tremor, but it usually begins much earlier than the more common sporadic form. It is part of the same broader biological pathway as Parkin, which is why the two genes are often discussed together.
Normal function
PINK1 encodes a mitochondrial kinase (protein that adds a phosphate group to other proteins) that helps cells monitor mitochondrial health. When mitochondria are damaged, PINK1 accumulates on the outer mitochondrial membrane and helps recruit and activate Parkin, initiating a quality-control program that tags damaged mitochondria for removal through the mitophagy pathway.
Mutation and effect
Pathogenic PINK1 mutations usually cause loss of function. This weakens the cell’s ability to detect and clear damaged mitochondria, allowing dysfunctional organelles to accumulate resulting in increased cellular stress, especially in neurons with high energy demand.
Key mechanisms involved
The main mechanisms involve mitochondrial dysfunction caused by defective mitophagy. Because mitochondria are central to ATP production and redox balance, PINK1 deficiency can shift cells into a state of chronic mitochondrial stress that becomes especially harmful in dopaminergic neurons. Oxidative stress and impaired metabolic resilience are downstream of this mitochondrial sickness.
Implications for treatment
There is no approved therapy that specifically corrects PINK1 loss, so treatment still largely follows standard Parkinson’s care, especially levodopa-based symptom management. Mechanistically, though, PINK1 has made the field much more interested in strategies aimed at improving mitochondrial quality control, mitophagy, and cellular stress resistance.
Research focus
Research on PINK1 is focused on restoring mitochondrial surveillance and identifying ways to rescue defective mitophagy. It is also a major model system for studying how mitochondrial stress feeds into broader Parkinson’s mechanisms such as ROS signaling, alpha-synuclein aggregation, and selective neuronal vulnerability.
Sources
- Lange, L. M., & Klein, C. (2024). PINK1 Type of Young-Onset Parkinson Disease.
- Morris, H., & Lim, S.-Y. (2025). Monogenic Parkinson Disease Overview.
- Kumar, A., Tamjar, J., Waddell, A. D., et al. (2017). Structure of PINK1 and mechanisms of Parkinson’s disease-associated mutations.
- Narendra, D. P., Jin, S. M., Tanaka, A., et al. (2024). The role of PINK1-Parkin in mitochondrial quality control.
- Valente, E. M., Abou-Sleiman, P. M., Caputo, V., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1.